glp-1 guidelines for weight loss Long-term Success of GLP-1s Hinges on More Than Just a Prescription GLP-1 is only for severely

Unlike other diabetes therapies, GLP-1 receptor demonstrates enhanced efficacy in reducing HbA1c levels and body weight

EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) was the first major trial published evaluating SGLT2-i use for reduction of MACE in patients with type 2 diabetes and known CVD on empagliflozin

The information provided reflects publicly available details from the company's website and general industry context

Novo Nordisk currently dominates the market for GLP-1 medications used for weight loss, while Eli Lilly's weight loss drug is expected to receive approval soon